Interferon-β1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis

Neurology

Volumn 46, Issue 6, 1996, Pages 1633-1638

  Brod, S A ^a   Marshall Jr , G D ^a   Henninger, E M ^a   Sriram, S ^b   Khan, M ^a   Wolinsky, J S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Vanderbilt Stallworth Rehabilitation Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD3 ANTIGEN; CONCANAVALIN A; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; METHOTREXATE; OKT 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROLIFERATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AUTOIMMUNE DISEASES; BIOLOGICAL RESPONSE MODIFIERS; CONCANAVALIN A; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; MUROMONAB-CD3; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029950889     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.6.1633     Document Type: Article

References (54)

1. Antel JP, Freedman MS, Brodsovsky S, Francis GS, Duquette P. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Ann Neurol 1989;25:204-207.
2. McFarlin D, McFarland H. Multiple sclerosis. N Engl J Med 1982;307:1183-1188.
3. Brod SA, Scott M. Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosis. Autoimmunity 1994; 17:143-148.
4. Brod SA, Khan M, Bright J, et al. Decreased CD3 mediated IFN-γ production in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:546-549.
5. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993;43:655-661.
6. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413.
7. Jacobs L, Cookfair D, Rudick R, et al. and the MS Collaborative Group. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann Neurol 1994;36;259.
8. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993;43:662-667.
9. Balkwill FR. The regulatory role of interferons in the human immune response. In: Taylor-Papadimitriou J, ed. Interferons: their impact in biology of medicine. Oxford: Oxford Medical Publications, 1985:61-80.
10. Rudick RA, Carpenter CS, Cookfair DL, Tuohy VK, Ransahoff RM. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon-beta. Neurology 1993;43: 2080-2087.
11. Byrne JA, Butler JL, Cooper MD. Differential activation requirements for virgin and memory T cells. J Immunol 1988; 141:3249-3257.
12. Horgan KJ, Van Seventer GA, Shimizu Y, Shaw S. Hyporesponsiveness of "naive" (CD45RA+) human T cells to multiple receptor mediated stimuli but augmentation of responses by co-stimuli. Eur J Immunol 1990;20:1111-1120.
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983;13:227-231.
14. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983;33: 1144-1452.
15. Quality Standards Committee, AAN. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994;44:1537-1539.
16. Brod SA, Burns DH. Suppression of relapsing experimental allergic encephalomyelitis in SJL/J mouse by oral administration of type I interferons. Neurology 1994;44:1144-1148.
17. Sanders ME, Makgoba MW, June CH, Young HA, Shaw S. Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor mediated activation. Eur J Immunol 1989; 19:803-808.
18. Morimoto C, Letvin NL, Distaso JA, Aldrich WR, Schlossman SF. The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 1985;134:1508-1512.
19. Morimoto C, Letvin NL, Rudd CE, Hagan M, Takeuchi T, Schlossman SF. The role of the 2H4 molecule in the generation of suppressor function in Con A-activated T cells. J Immunol 1986;137:3247-3253.
20. Koulova L, Yang SY, Dupont B. Identification of the anti-CD3-unresponsive subpopulation of CD4+ CD45RA+ peripheral T lymphocytes. J Immunol 1990;145:2035-2043.
21. Robinson AT, Miller N, Alexander DR. CD3 antigen-mediated calcium signals and protein kinase C activation are higher in CD45RO+ than in CD45RA+ human T lymphocyte subsets. Eur J Immunol 1993;23:61-68.
22. Budd RC, Cerottinin JC, MacDonald HR. Selectively increased production of IFN-γ by subsets of Lyt-2+ and L3T4+ T cells identified by expression of Pgp-1. J Immunol 1987;138: 3583-3586.
23. Bettens S, Walker C, Gauchat J-F, Gauchat D, Wyss T, Pichler WJ. Lymphokine gene expression related to CD4 T cell subset (CD45R/CDw29) phenotype conversion. Eur J Immunol 1989;19:1569-1574.
24. Bottomly K, Luqman M, Greenbaum L, et al. A monoclonal antibody to murine CD45R distinguishes CD4 T cell populations that produce different cytokines. Eur J Immunol 1989; 19:617-623.
25. low CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179: 589-600.
26. Salmon M, Kitas GD, Bacon PA. Production of lymphokine mRNA by CD45R+ and CD45R- helper T cells from human peripheral blood and by human CD4+ T cell clones. J Immunol 1989;143:907-912.
27. Mokhtarian F, Shi Y, Shirizian D, Morgante L, Miller A, Grob D. Defective production of anti-inflammatory cytokine, TGF-β, by T cell lines of patients with active multiple sclerosis. J Immunol 1994;152:6003-6010.
28. Kim J, Woods A, Becker-Dunn E, Bottomly K. Distinct functional phenotypes of cloned Ia-restricted helper T cells. J Exp Med 1985;162:188-201.
29. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cells. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2354.
30. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol 1987;138:3688-3694.
31. Boom WH, Liano D, Abbas AK. Heterogeneity of helper/ inducer T lymphocytes. II. Effects of interleukin-4 and interleukin-2 producing T cell clones on resting B cells. J Exp Med 1988;167:1350-1363.
32. Street N, Schumacher JH, Fong TAT, et al. Heterogeneity of mouse helper T cells: evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells. J Immunol 1990;144:1629-1637.
33. Ding L, Shevach E. IL-10 inhibits mitogen induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992;148:3313-3139.
34. Malefyt R, Haanen J, Spits H, et al. IL-10 and viral IL-10 strongly reduce antigen specific human T cell proliferation by diminishing the antigen presenting capacity of monocytes via downregulation of class II MHC expression. J Exp Med 1991; 174:915-924.
35. Merrill JE, Kono DH, Clayton J, Ando DG, Hinton DR. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci USA 1992;89:574-578.
36. Yssel H, Shanafelt M-C, Soderberg C, et al. Borrelia burgdorferai activates a T helper type-1 like T cell subset in Lyme arthritis. J Exp Med 1991;174:593-601.
37. Haanen J, Malefijt R, Res P, et al. Selection of a human T helper type 1-like T cell subset by Mycobacteria. J Exp Med 1991;174:583-591.
38. Brod SA, Benjamin D, Hafler DA. Restricted T cell expression of IL-2/IFN-γ mRNA in human inflammatory disease. J Immunol 1991;147:810-815.
39. Correale J, McMillan M, McKarthy K, Le T, Weiner LP. Patterns of cytokine production by PLP-specific T cell clones during the course of multiple sclerosis. Ann Neurol 1994;36:326.
40. Mosmann TR, Moore KW. The role of IL-10 in cross-regulation of Th1 and Th2 responses. Immunol Today 1991;12:A49-52.
41. Brod SA, Khan M. Oral administration of murine IFN-α is more effective than parenteral administration in the suppression of relapses in experimental autoimmune encephalomyelitis. J Autoimmun 1996;9:11-20.
42. Arnason BGW, Jensen M, Lledo A, Dayal A. Interferon β (IFN-β) induction in multiple sclerosis (MS) increases interferon γ (IFN-γ)-secreting cells [abstract]. Neurology 1995; 45(suppl 4):A437.
43. Baglioni C. 2′,5′-Oligo(A) pathway of interferon action. In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR eds. Interferon system. Austin, TX: UT Press, 1987:365-371.
44. Pestka S, Langer J, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987;56:727-777.
45. Weinstock-Guttmann B, Ransahoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanism of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
46. Noronha A, Toscas A, Jensen MA. IFN-β decreases T cell activation and IFN-γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-154.
47. Spear GT, Paulnock DM, Jordan RL, et al. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo b interferon. Clin Exp Immunol 1987;69: 107-115.
48. Baxevanis CN, Reclos GJ, Ansenis P, et al. Decreased expression of HLA-Dr antigens on monocytes in patients with MS. J Neuroimmunol 1989;22:177-183.
49. Baxevanis CN, Reclos GJ, Papamichail M. Decreased HLA-Dr antigen expression in monocytes causes impaired suppressor cell activity in MS. J Immunol 1990;146:4166-4171.
50. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today 1990;11:443-449.
51. Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988;9:137-139.
52. 2/interleukin 6 is a co-stimulant for human T lymphocytes. J Immunol 1988;141:1556-1562.
53. 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-7255.
54. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-38.